Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$2.24
-0.05 (-2.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $236.1M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-6.7%
↓Gross Margin
44.1%
↓Debt/Equity
0.33
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.6%
FCF CAGR
—
FCF margin
-6.9%
FCF / Net income
0.34x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.75B · net income $-357.1M · FCF $-119.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.75B | $1.75B | $2.10B | $2.97B | $2.71B |
| Net Income | $-357.1M | $-357.1M | $-377.0M | $84.3M | $79.0M |
| EBITDA | $-305.6M | $-305.6M | $-281.9M | $342.6M | $335.5M |
| EPS | -0.11 | -0.11 | -0.11 | 0.02 | 0.02 |
| Gross Margin | 44.1% | 44.1% | 46.6% | 64.1% | 59.4% |
| Operating Margin | -10.2% | -10.2% | -5.6% | 1.9% | 2.5% |
| Net Margin | -20.4% | -20.4% | -17.9% | 2.8% | 2.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.33 | 0.33 | 0.33 | 0.27 | 0.30 |
| Current Ratio | 2.13 | 2.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-119.8M | $-119.8M | $278.5M | $236.1M | $-371.7M |
| Returns | |||||
| ROE | -6.7% | -6.7% | -6.3% | 1.3% | 1.2% |
| Valuation | |||||
| P/E | — | — | — | 102.03 | 114.72 |
| EV/EBITDA | — | — | — | 21.67 | 22.30 |
| P/B | 1.30 | 1.30 | 1.33 | 1.31 | 1.39 |
| Growth & Yield | |||||
| Revenue Growth | -16.9% | -16.9% | -29.1% | 9.4% | — |
| EPS Growth | -2.2% | -2.2% | -554.9% | 6.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.11 → -0.11
Residual
-12.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.